Novartis China and Beijing Anzhen Hospital Announce Strategic Collaboration to Advance Cardiovascular Disease Prevention and Treatment

China Finance and Economics News, November 6th: Today, Novartis China and Beijing Anzhen Hospital, Capital Medical University ("Beijing Anzhen Hospital") signed a strategic cooperation memorandum at the site of the 7th China International Import Expo ("CIIE").

According to the Memorandum of Cooperation, both parties hope to leverage Novartis' research and development advantages in the field of cardiovascular diseases, while relying on the clinical research strength and comprehensive advantages of Beijing Anzhen Hospital, to promote the clinical research of products in the field of cardiovascular disease treatment, accelerate the process of innovative drug implementation, improve the prevention and treatment level of cardiovascular diseases, and benefit more patients with cardiovascular diseases. At the same time, the two parties also plan to promote academic exchanges and discipline co-construction at multiple levels, such as the frontier of the discipline and treatment concepts, through measures like building a talent exchange and "knowledge sharing" platform.

Cardiovascular diseases are the "number one killer" causing death among Chinese residents, and they are also a disease area where Novartis has long focused its efforts. Novartis pays close attention to patient needs, persists in innovative research and development, and continuously accelerates the introduction of breakthrough treatments for common cardiovascular conditions such as hypertension and hyperlipidemia in China. The company has successively introduced several innovative products in the cardiovascular field, providing more cutting-edge treatment options for the clinical prevention and control of cardiovascular diseases, and helping to bring about an early turning point in the battle against cardiovascular diseases in China.

Beijing Anzhen Hospital is a comprehensive tertiary Grade A hospital that focuses on the treatment of cardiovascular and pulmonary vascular diseases, integrating medical care, teaching, research, prevention, and international exchange. The hospital is one of the first National Clinical Research Centers for Cardiovascular Diseases and holds a leading position in the cardiovascular field in China. In recent years, the hospital has continuously enhanced its overall strength around its key disciplines, forming a comprehensive discipline group with cardiology at its core and multi-disciplinary collaborative development, providing high-quality medical services for patients with various comorbid heart conditions.

Cai Jun, President of Beijing Anzhen Hospital, stated that as a leading medical institution in the research and treatment of cardiovascular diseases, Beijing Anzhen Hospital continues to make efforts in the direction of scientific research innovation, promoting the close integration of basic research and clinical application. "Novartis is a globally leading company focusing on innovative drugs and has accumulated extensive experience in the research and development of cardiovascular diseases. We look forward to achieving complementary advantages and resource sharing through our strategic cooperation with Novartis, promoting high-quality clinical research and translation, ultimately benefiting more cardiovascular patients in China."

"Cardiovascular is one of the core therapeutic areas that Novartis focuses on. We are always committed to working with top medical institutions in China to promote the prevention and treatment of cardiovascular diseases in China. The annual CIIE is undoubtedly an excellent opportunity to promote exchanges and achieve cooperation," said Dr. Anfan Wu, Head of Translational Medicine at Novartis China. Anzhen Hospital, Beijing is the 'national team' in the field of cardiovascular disease medical science and technology innovation, and we hope that through cooperation, we can jointly explore new models for product development and clinical research in the cardiovascular field, leverage synergies, improve the level of cardiovascular disease prevention and treatment, and help achieve the goal of Healthy China.